NCT01173822

Brief Summary

The study is an randomized controlled trial (RCT) of 198 coronary artery bypass graft (CABG) patients, exploring whether ultrafiltration of residual blood in the cardiopulmonary bypass circuit reduces transfusion and bleeding.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
200

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Dec 2004

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 1, 2004

Completed
2.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2007

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2007

Completed
3.3 years until next milestone

First Submitted

Initial submission to the registry

July 16, 2010

Completed
17 days until next milestone

First Posted

Study publicly available on registry

August 2, 2010

Completed
Last Updated

August 2, 2010

Status Verified

July 1, 2010

Enrollment Period

2.3 years

First QC Date

July 16, 2010

Last Update Submit

July 30, 2010

Conditions

Keywords

cardiopulmonary bypasshemorrhagetrialssurgery

Outcome Measures

Primary Outcomes (1)

  • the proportion of patients transfused with homologous red blood cells (RBC)

    At 30 days post-operatively

Secondary Outcomes (5)

  • Proportion of patients transfused with any blood product

    At 30 days post-operatively

  • Volume of pRBC's transfused post-operative

    At 30 days post-operatively

  • Post-operative hemorrhage

    At 24 hours post-operative

  • Discharge Hemoglobin

    A date of discharge, median 5 days in study

  • Length of hospital stay

    From day to surgery to discharge, median 5 days in this study

Study Arms (2)

Treatment group

EXPERIMENTAL

Ultra filtration of residual blood.

Other: Ultrafiltration of residual blood

Control

NO INTERVENTION

The current practice in our institution was to displace all the remaining volume in the CPB circuit into a transfer pack by displacing the remaining blood in the CPB circuit with additional Lactated Ringers solution. This transfer pack is then given to the anesthetist for reinfusion into the patient.

Other: Ultrafiltration of residual blood

Interventions

The inflow line to the hemoconcentrator was connected to the sideport of the arterial filter stopcock, allowing the residual blood in the CPB circuit to be processed through the hemoconcentrator. The outflow line from the hemoconcentrator was connected to a second three way stopcock located on the cardiotomy reservoir. Blood was circulated from the venous reservoir through the hemoconcentrator and returned to the venous reservoir until the desired hematocrit was achieved. The blood was then diverted to a transfer pack until all the blood from the venous reservoir, heat exchanger, and membrane oxygenator had been filtered and hemoconcentrated. This transfer pack was given to the anesthetist for reinfusion into the patient.

ControlTreatment group

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • at least 18 years of age
  • were to undergo isolated on-pump CABG
  • were able to give informed consent

You may not qualify if:

  • performed autologous blood donation
  • underwent off-pump CABG
  • emergency procedure
  • resternotomy
  • known bleeding disorder not drug related
  • history of heparin-induced thrombocytopenia
  • Jehovah's Witness
  • intra-operative catastrophe prior to randomization

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hamilton General Hospital

Hamilton, Ontario, L8L2X2, Canada

Location

Related Publications (1)

  • Whitlock R, Mathew J, Eikelboom J, Al-Saleh AM, Yuan F, Teoh K. Processed residual pump blood in cardiac surgery: the Processed Residual Blood in Cardiac surgery trial. Transfusion. 2013 Jul;53(7):1487-92. doi: 10.1111/j.1537-2995.2012.03958.x. Epub 2012 Nov 26.

MeSH Terms

Conditions

Hemorrhage

Condition Hierarchy (Ancestors)

Pathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Richard Whitlock, MD MSc

    Hamilton Health Sciences Corporation

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER

Study Record Dates

First Submitted

July 16, 2010

First Posted

August 2, 2010

Study Start

December 1, 2004

Primary Completion

April 1, 2007

Study Completion

April 1, 2007

Last Updated

August 2, 2010

Record last verified: 2010-07

Locations